(RTTNews) - Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and artificial intelligence across manufacturing and quality processes.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.